Italia markets close in 2 hours 44 minutes

ADMA Biologics, Inc. (ADMA)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
2,4600-0,0100 (-0,40%)
Alla chiusura: 4:00PM EST

2,3800 -0,08 (-3,25%)
Before hours: 8:43AM EST

ADMA Biologics, Inc.

465 State Route 17
Ramsey, NJ 07446
United States
201 478 5552
http://www.admabiologics.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno313

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Adam S. GrossmanCo-Founder, Pres, CEO & Director941,16kN/D1977
Dr. Jerrold B. Grossman Ph.D., D.P.S.Co-Founder & Vice Chairman70,9kN/D1948
Mr. Brian Lenz CPA, CPAExec. VP & CFO741,73kN/D1972
Dr. James MondExec. VP, Chief Scientific Officer & Chief Medical Officer856,99kN/D1946
Ms. Kim TripodoExec. Director & Head of Human Resource and Admin. OperationsN/DN/DN/D
Mr. Skyler BloomDirector of Investor Relations & Corp. StrategyN/DN/DN/D
Ms. Kaitlin KestenbergVP of Compliance, Project Management & Clinical OperationsN/DN/DN/D
Mr. Michael LeastVP of Sales & Commercial OperationsN/DN/DN/D
Mr. Drew PantelloVP of Marketing & Corp. Devel.N/DN/DN/D
Dr. Gene A. Wetzstein BCOP, Pharm.D.Exec. Director & Head of Scientific EngagementN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2019 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di ADMA Biologics, Inc. al 22 gennaio 2021 è 7. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.